Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Akebia Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AKBA
Nasdaq
2834
https://akebia.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Akebia Therapeutics Inc
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
- May 14th, 2024 12:00 pm
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
- May 11th, 2024 1:21 pm
Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
- May 10th, 2024 7:27 pm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
- May 10th, 2024 7:06 pm
Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
- May 10th, 2024 1:19 pm
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
- May 9th, 2024 12:10 pm
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- May 9th, 2024 11:00 am
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
- May 2nd, 2024 12:30 pm
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 1st, 2024 8:05 pm
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
- Apr 28th, 2024 2:23 pm
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
- Mar 28th, 2024 3:50 pm
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
- Mar 28th, 2024 11:06 am
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
- Mar 28th, 2024 12:26 am
Akebia Awaits FDA Word On Second Crack At Vadadustat
- Mar 26th, 2024 5:12 pm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
- Mar 17th, 2024 1:25 pm
Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
- Mar 16th, 2024 1:22 pm
Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
- Mar 14th, 2024 9:51 pm
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
- Mar 14th, 2024 9:30 pm
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Mar 14th, 2024 8:15 pm
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
- Mar 11th, 2024 9:05 pm
Scroll